PPD Acquires BioDuro

PPD (Pharmaceutical Product Development) has completed its acquisition of BioDuro. With this acquisition, PPD now employs more than 1,400 in Asia Pacific and nearly 1,000 people in China, to offer clinical development and discovery services in the country. PPD has paid approximately $77m in cash to acquire BioDuro.

PPD has signed an agreement to acquire BioDuro on November 18, 2009. Previously, the company said that the acquisition will expand PPD’s drug development capabilities in China.

As announced, PPD has recently acquired Excel PharmaStudies, expanding PPD’s Phase II-IV clinical, data management, biostatistics, regulatory and quality assurance services. PPD has offices throughout Asia Pacific in addition to global central lab facilities in China and Singapore.

David Grange, CEO of PPD, said: “Our acquisition of BioDuro positions us to capitalise on the tremendous growth in Asia Pacific and to become the CRO of choice in China. BioDuro has a premier reputation for delivering quality service and has built an exceptional team of researchers and scientists. We are very pleased to welcome BioDuro’s 660 employees into PPD.”